Conclusions
Clinical and microbiologic results of this study support, preliminarily, that telavancin is an effective antimicrobial agent for the treatment of infection due to MRSA.
This is a preview of subscription content, log in via an institution to check access.
References
Fridkin SK, Hageman JC, Morrison M, et al.: Methicillinresistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1485–1487.
Miller LG, Perdreau-Remington F, Rieg G, et al.: Necrotizing fasciitis caused by community-associated methicillinresistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445–1453.
Van BambekeF, Van Laethem Y, Courvalin P, Tulkens PM: Glycopeptide antibiotics. From conventional molecules to new derivatives. Drugs 2004, 64:913–936.
Raad I, Darouiche R, Vazquez J, et al.: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005, 40:374–380.
Shaw JP, Seroogy J, Kaniga K, et al.: Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005, 49:195–201.
Stryjewski ME, O’Riordan WD, Lau WK, et al.: Telavancin versus standard therapy for treatment of complicated skin and soft tissue infections due to gram-negative bacteria. Clin Infect Dis 2005, 40:1601–1607.
NathwaniD: Tigecycline: clinical evidence and formulary positioning. International J Antimicrob Agents 2005, 25:185–192.
Yin LY, Lazzarini L, Li F, et al.: Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005, In press.
Rights and permissions
About this article
Cite this article
Tan, J.S. New antimicrobial agents active against Staphylococcus aureus . Curr Infect Dis Rep 7, 357–358 (2005). https://doi.org/10.1007/s11908-005-0009-x
Issue Date:
DOI: https://doi.org/10.1007/s11908-005-0009-x